Explore our website for the latest on MPN Specialist in the U.S. Doctor-reviewed and … Learn More
Breakthrough CALR Therapy Shows High Response Rate in ET
by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
Rusfertide Cuts Phlebotomies by 77% in Polycythemia Vera
by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]
Help advance Myelofibrosis research from home
PV Reporter, in partnership with Sanguine Biosciences, is reaching out to raise awareness about an at-home research opportunity for patients diagnosed with Myelofibrosis. What is the goal of the at-home research? The goal of this research is to enhance their understanding of Myelofibrosis, in support of developing new diagnostic and treatment options for patients living […]
Chet Lemon Dies from PV Complications at 70
Chet Lemon, a beloved former Major League Baseball outfielder and 1984 World Series winner, died at the age of 70. Lemon passed on Thursday, May 8, 2025, after a decades-long battle with polycythemia vera (PV), a rare blood disorder, and its associated complications. Lemon, a three-time All-Star, was diagnosed with polycythemia vera in 1990, toward […]
FDA Grants Fast Track to Givinostat for Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat, an oral histone deacetylase inhibitor (HDACi) developed by Italfarmaco S.p.A., for the treatment of polycythemia vera (PV), a rare hematologic malignancy. This designation aims to expedite the development and review of drugs that address serious conditions with unmet medical needs. PV […]
- 1
- 2
- 3
- …
- 44
- Next Page »
